BiotechTube

Bortezomib

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myelodysplastic Syndromes

Conditions

Myelodysplastic Syndromes

Trial Timeline

Jun 1, 2006 → Aug 1, 2011

NCT ID
NCT00411905

About Bortezomib

Bortezomib is a phase 1/2 stage product being developed by Johnson & Johnson for Myelodysplastic Syndromes. The current trial status is completed. This product is registered under clinical trial identifier NCT00411905. Target conditions include Myelodysplastic Syndromes.

What happened to similar drugs?

7 of 19 similar drugs in Myelodysplastic Syndromes were approved

Approved (7) Terminated (7) Active (7)
✅decitabine + azacitidineEisaiApproved
✅DeferasiroxNovartisApproved
✅ICL670/DeferasiroxNovartisApproved
✅deferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅DeferasiroxNovartisApproved
✅Epoetin betaRocheApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT02268890ApprovedCompleted
NCT01801436Phase 3Completed
NCT00411905Phase 1/2Completed
NCT00111319Phase 3Completed

Competing Products

20 competing products in Myelodysplastic Syndromes

See all competitors
ProductCompanyStageHype Score
NEX-18a injection + Azacitidine InjectionNanexa ABPhase 1
23
JSP191Jasper TherapeuticsPhase 1
11
Humanized anti-CD117 Monoclonal Antibody (JSP191)Jasper TherapeuticsPhase 1
15
GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase IIGT BiopharmaPhase 1/2
14
Erlotinib HydrochlorideAstellas PharmaPhase 2
35
Decitabine + Decitabine + DecitabineEisaiPhase 2
35
Decitabine + Valproic AcidEisaiPhase 2
35
decitabine + decitabineEisaiPhase 2
35
decitabine + azacitidineEisaiApproved
35
DecitabineEisaiPhase 2
27
decitabine + decitabine + decitabine + decitabineEisaiPhase 1
29
Decitabine, Arsenic Trioxide and Ascorbic AcidEisaiPhase 2
35
Subcutaneous DecitabineEisaiPhase 1
21
DecitabineEisaiPhase 2
35
Galunisertib + PlaceboEli LillyPhase 2/3
38
DSP-7888Sumitomo PharmaPhase 1/2
32
TP-0184Sumitomo PharmaPhase 1/2
24
DecitabineJohnson & JohnsonPhase 2
35
Epoetin alfaJohnson & JohnsonPhase 2
27
ZARNESTRA, tipifarnib, R115777Johnson & JohnsonPhase 2
35